Loading...
•
Jun 30, 2023
Heron Therapeutics Q2 2023 Earnings Report
Heron Therapeutics reported an increase in oncology care franchise net product sales and is focused on cost reduction program.
Key Takeaways
Heron Therapeutics announced its Q2 2023 financial results, highlighting a focus on resizing the business and a cost reduction program expected to save approximately $75 million through 2025. The company also completed a $30 million equity financing and closed a $50 million working capital facility to bolster its balance sheet.
Company is well capitalized after signing $50 million working capital credit facility and recent $30 million equity raise
Favorable outcome at Markman hearing in pending CINVANTI® ANDA patent litigation
New management team in place
Reiterating full-year net product sales guidance for the oncology care franchise of $99-$103 million
Heron Therapeutics
Heron Therapeutics
Heron Therapeutics Revenue by Segment
Revenue by Segment
CINVANTI Revenue
CapyFin.comSUSTOL Revenue
CapyFin.comZYNRELEF Revenue
CapyFin.comAPONVIE Revenue
CapyFin.com Forward Guidance
Heron is reiterating full-year 2023 net product sales guidance for the oncology care franchise of $99 million to $103 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income